Aculeacin A is a cyclopeptide-containing long-chain fatty acid, representing a new class of antibiotics.
Aculeacin A is the major component of a mixture of new antifungal antibiotics produced by Aspergillus aculeatus.1) The chemical structure of aculeacin A is closely related to that of echinocandin B which is a polypeptide with a fatty acid residue.2,3) Preliminary information revealed that aculeacin A is highly active in vitro against Candida albicans and several other yeasts, while it has very slight activity against a number of fungi and is inactive against bacteria.1) Studies therefore were undertaken to further define the in vitro antifungal spectrum and other in vitro properties of this antibiotic. Where appropriate, the antifungal activity of aculeacin A was compared with clotrimazole, a drug of choice used in treatment of several groups of superficial mycotic infections. Materials and Methods
Drugs
Aculeacin A (Toyo Jozo Co., Ltd., Tokyo) and clotrimazole (bis-phenyl-(2-chloro-phenyl)-1-imidazolylmethane;
Bayer-Yakuhin Co., Ltd., Osaka) were dissolved in 100% dimethyl sulfoxide. Final stock drug solutions of the two drugs were further diluted to contain 8 mg of active material per ml.
Organisms
One hundred and thirteen strains of fungi, most of which are of medical interest, were tested (Tables   1 -3 ). These consisted of clinical isolates and stock cultures in our laboratory.
Preparation of Inocula
Stock cultures of monomorphic yeasts (Candida, Torulopsis and Cryptococcus) were grown at 27°C for 3 days on Sabouraud glucose (SG) agar medium, and those of filamentous and dimorphic fungi were grown for 3 weeks on the same medium.
Viable-cell suspensions of monomorphic yeasts were prepared by suspending viable cells harvested from 3-day-old SG agar slants in sterile saline.
Spore suspensions of filamentous fungi or dimorphic fungi were prepared by rubbing on the surface of 20-day-old SG agar slants with a loop after the addition of sterile saline containing 0.1 % (w/v) Tween 80. Then they were filtered through two layers of gauze or allowed to stand at room temperature for settle down large blocks of cell aggregates or mycelia. All inocula were adjusted by nepherometry with sterile saline with or without 0.1 % Tween 80 so as to contain from 10° to 10' cells or spores per ml as confirmed by viable plate counts. Media SG agar medium and SG broth were used. The pH was 5.6.
Susceptibility Testing
The agar dilution method was used. Drugs were diluted in the SG agar medium over a final concentration range of 0.01 to 80 ug per ml. Here 0.003 ml of cell or spore suspensions was inoculated by making a 2 cm-long streak with the calibrate loop, and the plate was incubated at 27'C, except for Candida spp., which preferred 37°C, for the indicated period of time that sufficed to show appreciable growth of colonies on drug-free control plates. The minimum growth-inhibitory concentration (MIC) was defined as the lowest concentration of drug at which there was no visible growth.
Effect of pH on Activity
The MIC of aculeacin A against fungi on medium with different pH values was determined by the agar dilution method on SG agar medium adjusted to a final pH value ranging from 3.0 to 8.0 with 0.1 M glycine-HCl buffer (pH 3 ~ 5) and 0.1 M phosphate buffer (pH 5 -8) . Six strains of C. albicans were used as the test organism with an inoculum size of 0.03 ml of 106 viable cells per ml.
Effect of Inoculum Size on Activity
The MIC of aculeacin A against C. albicans with different inoculum sizes was determined by the agar dilution method on SG agar medium (pH 5.6) with an inoculum size of 0.003 ml of l04, 105, 3x 105, 106, 107, and 108 viable cells per ml.
Effect of Human Serum on Activity _
The effect of serum on the MIC of aculeacin A against C. albicans was determined by the agar dilution method on SG agar medium containing 10% human serum with an inoculum size of 0.003 ml of 10° viable cells per ml.
Fungicidal Activity Test
A series of L-tubes containing 9 ml of SG broth incorporating from 0 to 20 itg of aculeacin A per ml was prepared, and inoculated with 0.1 ml of viable cell suspensions of C. albicans to give final cell concentrations of approximately 106, 107 and 108 colony forming units (CFU) per ml. After incubation at 37°C for 6 hours on a shaker, samples were taken from each tube, and aliquots (0.1 nil) from serial dilutions were plated on SG agar plates with the aid of spreaders for counts of CFU. No significant drug carry-over was detected at the lowest dilution used.
Results

In Vitro Antifungal Spectrum
The in vitro antifungal activity of aculeacin A and clotrimazole against a variety of pathogenic yeasts and filamentous fungi is shown in Tables 1, 2 and 3. Data for clotrimazole, which are consistent with previously published results,4~6) show that clotrimazole indeed had a broad spectrum of activity against yeasts and filamentous fungi. By contrast, the antifungal spectrum of aculeacin A was much less in wideness.
As shown in Table 1 , aculeacin A was highly active against C. albicans and other Candida species as well as Torulopsisglabrata; the MIC range was <0.04 to 5 fig per ml, and the order of activity appeared to be much greater than with clotrimazole.
In particular, C. albicans was inhibited by aculeacin A at levels around 0.1 Feg per ml or less. Contrary to these aculeacin A-sensitive yeasts, Cryptococcur neofornians lacked the sensitivity to this antifungal antibiotic; the MIC for all strains of C. neofor- C. tropicalis (4) C. pseudotropicalis (4) C. krusei (2) C. parapsilosis (2) C. stellatoidea (2) C. guilliernzondii (2) Torulopsis glabrata (4) Cryptococcus neoforinans (9) All MIC values were read after 4 days. All MIC values were read after 14 days, except for those against As fiunigatus which were read after 7 days. mans tested was more than 80 pg per ml.
The spectrum of activity against some opportunistic filamentous fungi, such as Aspergillusfumigatus, and dematiaceous fungi is presented in Table 2 and that against dermatophytic fungi is given in Table 3 .
With the only exception of a strain of Trichophyton tonsurans, all these varying groups of fungi were not inhibited by aculeacin A at any levels up to 80 pg per ml, although partial inhibition was observed with almost all strains at much lower drug concentrations.
Influence of pH, Inoculum Size, Incubation Time, and Serum on In Vitro Activity
The results of experiments which were carried out using 6 laboratory strains of C. albicans on SG agar medium with a pH value of 3 to 8 show that the MIC value was virtually unaffected over the entire pH range tested (Table 4) . All MIC values were read after 14 days. Viable counts were determined after 6 hours of incubation at 37`C.
values against other strains, like MTU 12084, appeared to be not influenced by inoculum size nor incubation time. Table 5 also demonstrates that, in the presence of 10 % human serum, there was a 50-fold or greater increase in the MIC, which was read after 2 days of incubation, for both types of C. albicans strains. Moreover, on the serum-supplemented medium, not only the inoculum effect but the incubation time effect on the MIC of aculeacin A against the former type of strains, such as MTU 12021, was cancelled.
Fungicidal Action of Aculeacin A Experiments were conducted using two strains of C. albicans to examine whether aculeacin A primarily acts on sensitive yeasts as a fungistatic agent or a fungicide. The survival of C. albicans strains MTU 12021 and MTU 12084 after 6 hours of exposure to various concentrations of aculeacin A is shown in Fig. 1 . It can be seen that both strains behaved in a similar fashion, irrespective of different inoculum sizes, in that 0.08 to 0.31 tig of aculeacin A per ml was most lethal ; more than 99% kill occurred within the experimental period of time, and that further increases in the concentration of the antibiotic progressively reduced its fungicidal effect. Essentially the same dose-response pattern was obtained for other strains of C. albicans, as well as strains of other species of sensitive yeasts such as C. tropicalis and T. glabrata. Thus the results show that the dose-response pattern elicited by aculeacin A was neither strain nor species specific.
Discussion
The results of this expanded in vitro study indicate that aculeacin A is highly active against Candida and Torulopsis yeasts while it is poorly active or inactive against Cryptococcus yeasts and all the pathogenic filamentous fungi tested including various dimorphic, dematiaceous and dermatophytic fungi. Thus the antibiotic shows a considerably restricted spectrum of activity against several yeasts. A very similar antifimgal spectrum has been reported with the structurally related antibiotics echinocandin BT) and papulacandins.8,9) For some unknown reasons, the aculeacin A-sensitivity of some strains of sensitive yeasts was markedly influenced by inoculum size and incubation time. It is desirable, therefore, to express the MIC of the antibiotic against Candida and other yeasts as a value determined after 2 days or, at most, 4 days of incubation using relatively small inoculum sizes.
Previous studies made by other investigators on the biochemical and cytological effects of aculeacin A revealed that it preferentially inhibits de novo synthesis of cell wall, particularly wall glucan, eventually leading to cell lysis in growing cells of Saccharomyces cerevisiae and Schizosaccharomyces pombe.1o.11° This may explain the basal mechanism by which aculeacin A exerts potent fungicidal action toward sensitive yeasts.
Aculeacin A appears unusual among antifungal agents in respect to the dose-response pattern elicited by aculeacin A-sensitive yeasts. Data are presented to illustrate that when aculeacin A was used in vitro to treat C. albicans, it was most lethal at a concentration range between 0.08 and 0.31 pg per ml, above which concentration range the drug became decreasingly lethal. This paradoxic effect of aculeacin A would be analogous to that previous described for the action of penicillin against some Grampositive and -negative bacteria 12, 13) and for the action of nalidixic acid against Escherichia coli and some other Gram-negative bacteria.14,15) Our current interest is in elucidating a mechanism that explains the paradoxic dose-response behavior of C. albicans to aculeacin A, along with a mechanism of its antifungal action.
The therapeutic implications of the paradoxic effect of aculeacin A is difficult to assess. Probably it has no serious clinical implication, since it is shown that this anomalous effect is cancelled by serum, and the antibiotic is highly bound to serum. Studies are needed to assess the relevancy of this serum binding phenomenon to the utility of aculeacin A in chemotherapy.
Apart from therapeutic applications as an antifungal agent, the selectivity of the fungicidal action OF ANTIBIOTICS VOL. XXXV NO. 2 of aculeacin A suggests its usefulness for taxonomical grouping of yeasts.
In this expectation, aculeacin
A-sensitivity of a wider range of yeast species is being explored.
